Acelrx pharmaceuticals announces abstract acceptance for podium presentation at the anesthesiology® 2022 annual meeting

Hayward, calif. , aug. 10, 2022 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx), (acelrx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that an abstract, entitled, "the impact of sublingual sufentanil on postoperative pain control in patients undergoing spine surgery" (abstract # a4262) was accepted for e-abstract presentation at the anesthesiology® 2022 annual meeting, being held october 21-25, 2022 in new orleans, la.
ACRX Ratings Summary
ACRX Quant Ranking